Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2006

View Archived Issues

Novagali completes phase II study of ophthalmic formulation of ciclosporin

Chemicon and MorphoSys sign licensing agreement for research antibodies

Lantibio and TRB Chemedica sign agreement for Vismed

Canadian clearance for phase I study of SL-017 for acne and hair removal

Avid Radiopharmaceuticals closes first institutional financing round

Connetics to acquire PediaMed sales organization

SIRT1 activation: a new target for AD / News in Context

SB-509 set for phase II trial in diabetic neuropathy in H2 2006

New maintenance study of Peg-Intron in HCV patients coinfected with HIV

Hana Biosciences reports 2005 and 2006 milestones

Human Genome Sciences and Amgen sign license agreement

New peripherally selective DBH inhibitor from BIAL

Vitor shows therapeutic effect in cancer cachexia

Lucentis maintained or improved vision in approximately 95% of patients at one year

Benefits of memantine sustained for 1 year in Alzheimer's disease patients

Dosing, pharmacokinetics of BAY-43-9006 investigated in cancer patients

Interleukin-2 improves efficacy of WX-G250 in renal cell carcinoma

4F-Benzoyl-TE-14011 investigated in metastatic bladder cancer

BXL-628 can reduce prostate volume in benign prostatic hyperplasia

Fourth quarter update from Genzyme

New agents described for treating cardiovascular disorders

New possible treatments for gastrointestinal disorders described in recent patents

Recent GSK patent imparts novel agents for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.